Jung Choi - 27 Sep 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Officer Title: Chief Business and Strategy Officer
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
GBT
Transactions as of
27 Sep 2022
Transactions value $
$699,994
Form type
4
Filing time
29 Sep 2022, 20:43:36 UTC
Previous filing
06 Sep 2022
Next filing
06 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise $277K +16.9K +8.41% $16.40* 218K 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $150K +2.28K +1.04% $65.82 220K 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $255K +75K +34.04% $3.40* 295K 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $9.09K +2.67K +0.91% $3.40* 298K 27 Sep 2022 Direct
transaction GBT Common Stock Options Exercise $9.09K +2.67K +0.9% $3.40* 301K 27 Sep 2022 Direct
transaction GBT Common Stock Gift $0 -73.9K -24.58% $0.00 227K 29 Sep 2022 Direct
holding GBT Common Stock 25K 27 Sep 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -16.9K -34.49% $0.00 32.1K 27 Sep 2022 Common Stock 16.9K $16.40 Direct F1
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -2.28K -5.91% $0.00 36.2K 27 Sep 2022 Common Stock 2.28K $65.82 Direct F2
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -75K -100% $0.00* 0 27 Sep 2022 Common Stock 75K $3.40 Direct F3
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -2.67K -99.96% $0.00 1 27 Sep 2022 Common Stock 2.67K $3.40 Direct F4
transaction GBT Stock Option (Right to Buy) Options Exercise $0 -2.67K -99.96% $0.00 1 27 Sep 2022 Common Stock 2.67K $3.40 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021.
F2 The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F3 The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 77,142 shares on April 6, 2016 and in 12 equal quarterly installments thereafter through April 6, 2019.
F4 On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
F5 On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.

Remarks:

Officer Title: Chief Business and Strategy Officer